Alfian Pramudita Putra*, .- and Dyah Hikmawati, .- and Aniek Setiya Budiatin, .- (2019) Injectable Bone Substitute of Hydroxyapatite-Gelatin Composite with Alendronate for Bone Defect Due to Osteoporosis. Journal of International Dental and Medical Research, 12 (2). pp. 813-818. ISSN 1309-100X

	Text (Fulltext) C07. Fulltext.pdf Download (960kB)
	Text (Penilaian dan Validasi) C07. Penilaian dan Validasi.pdf Download (761kB)
	Text (Similarity) C07. Simillarity.pdf Download (2MB)

Abstract

World Health Organization mentioned that there were 200 million people in the world suffered from osteoporosis in 2013 and half of them has bone fractures. Hydroxyapatite as a bioactive material was explored as a substitute for bone defect or osteoporosis. The conventional bone filler was lack of the ability to let the filler to fill the irregular defect due to osteoporosis. Thus, a new method was introduced called an injectable bone substitute. While the bone filler performs its function to stabilize the mechanical property of the defected bone, the addition of a drug, such as an alendronate, would be beneficial. The injectable bone substitute (IBS) based on hydroxyapatitegelatin was synthesized with the addition of alendronate. The Fourier Transform Infrared (FTIR) result showed a bond formation of hydroxyapatite and gelatin by shifting of carboxyl group wavenumber from 1332,72 cm-1 to 1559-1543 cm-1 from gelatin with Ca2+ from hydroxyapatite. The IBS viscosity was (38.7±0.53) dPa.s and was able to be extruded from the syringe. The IBS could become suspension again after sedimentation and did not change the pH of SBF solution. The IBS was precipitated with a suitable substrate. The cytotoxicity test showed that the samples were nontoxic. The results of IBS characterizations demonstrated that it has potential to be used as a bone filler as well as drug delivery system to the bone defect due to osteoporosis.

Actions (login required)

View Item